OCGN
HEALTHCAREOcugen Inc
AI Insight
What's Moving OCGN Today?
No stock-specific AI insight has been generated for OCGN yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.90$2.73
$1.38
Fundamentals
Market Cap$437M
P/E Ratio—
EPS$-0.24
Dividend Yield—
Dividend / Share—
ROE-660.0%
Profit Margin—
Debt / Equity—
Trading
Volume8.2M
Avg Volume (10D)—
Shares Outstanding338.5M
OCGN News
23 articles- How The Ocugen (OCGN) Investment Story Is Evolving Without New Analyst GuidanceYahoo Finance·Jun 6, 2026
- Why Is Ocugen (OCGN) Down 10.7% Since Last Earnings Report?Yahoo Finance·Jun 4, 2026
- Ocugen's Gene-Agnostic Eye Therapies Could Reshape Late-Stage CareYahoo Finance·Jun 3, 2026
- Is OCGN Stock Worth the Risk Ahead of 2026-27 Eye Gene Therapy Data?Yahoo Finance·Jun 3, 2026
- OCGN's Catalyst Calendar for Trial Data and Filings Through 2028Yahoo Finance·Jun 3, 2026
- Ocugen to Participate in Upcoming June Investor and Industry ConferencesYahoo Finance·Jun 2, 2026
- CCORF Maintains Ocugen(OCGN.US) With Buy Rating, Cuts Target Price to $11Moomoo·May 27, 2026
- Ocugen, Inc. Announces Closing for $130.0 Million of 6.75% Convertible Senior NotesYahoo Finance·May 14, 2026
- Ocugen to Participate in Upcoming May Scientific and Investor ConferencesYahoo Finance·May 13, 2026
- Ocugen (OCGN) Reports Q1 EPSInsider Monkey·May 13, 2026
- Ocugen (OCGN) Is Down 16.8% After $115M Convertible Notes Deal And Wider Q1 Losses Has The Bull Case Changed?Yahoo Finance·May 9, 2026
- Ocugen (OCGN) Upgraded to Buy: Here's WhyYahoo Finance·May 8, 2026
- Number of shareholders of Ocugen Inc – LSX:A2PSZHTradingView·May 8, 2026
- OCGN Falls on Wider Q1 Loss Despite Strong Pipeline Progress OutlookYahoo Finance·May 6, 2026
- Ocugen Q1 Earnings Call HighlightsMarketbeat·May 5, 2026
- Ocugen (OCGN) Reports Q1 Loss, Beats Revenue EstimatesYahoo Finance·May 5, 2026
- Ocugen Provides Business Update with First Quarter 2026 Financial ResultsYahoo Finance·May 5, 2026
- Ocugen, Inc. Announces Pricing of $115 Million of 6.75% Convertible Senior NotesYahoo Finance·May 5, 2026
- Ocugen Announces Private Offering of $115 Million of Convertible Senior NotesYahoo Finance·May 4, 2026
- Ocugen (OCGN) Completes Enrollment for Phase 2/3 Pivotal Trial of OCU410ST Gene TherapyYahoo Finance·May 1, 2026
- Ocugen to Host Conference Call on Tuesday, May 5 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2026 Financial ResultsYahoo Finance·Apr 29, 2026
- How The Ocugen (OCGN) Story Is Shifting With Gene Therapy Milestones And Valuation DebateYahoo Finance·Apr 26, 2026
- Biotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated CellsBenzinga·Apr 10, 2026
All 23 articles loaded
Price Data
Open$1.28
Previous Close$1.29
Day High$1.43
Day Low$1.28
52 Week High$2.73
52 Week Low$0.90
52-Week Range
$0.90$2.73
$1.38
Fundamentals
Market Cap$437M
P/E Ratio—
EPS$-0.24
Dividend Yield—
Dividend / Share—
ROE-660.0%
Profit Margin—
Debt / Equity—
Trading
Volume8.2M
Avg Volume (10D)—
Shares Outstanding338.5M
About Ocugen Inc
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the development of gene therapies to cure diseases of blindness. The company is headquartered in Malvern, Pennsylvania.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—